Read Larry Connors' blog – Short Term Trading Strategies
Celling Technologies is committed to developing cell processing and separation technologies that produce consistently high yields of mononuclear cells. The Res-Q provides a complimentary portable option to the MXP for high yield point-of-care cell separation. As the regenerative medicine market continues to mature, Celling and ThermoGenesis have committed research and development efforts focused on surgeon, patient and hospital needs while further investigating the broader therapeutic capabilities of adult stem cells. Celling Technologies continues to grow its team of 52 employees with additional scientists, engineers and healthcare providers to develop unique cell processing and delivery systems, cell analysis tools and a healthcare-focused service model.
Dr. Mustasim Rumi of Round Rock Orthopedics recently utilized Celling Technologies and the ThermoGenesis' design team's latest technology in adult stem cell spine therapy.
"The RES-Q system was able to yield a high concentration of mononuclear cells which I believe is one of the key ingredients to bone growth," said Rumi. "This technology and Celling's service team provided me with the confidence that the cells being processed and the sterility of the procurement is the best in the industry. The market of regenerative therapies will change medicine and I believe that such cutting-edge companies give me the best opportunity to deliver the highest care to my patients."
The future of regenerative medicine is being driven by technical advancement in cell preparation and processing and the investment of outcome-based clinical studies. Celling Technologies' experience in the delivery and clinical evaluation of stem cell therapies, combined with ThermoGenesis' expertise in cell fractionation, isolation and characterization, make for a team that will continue to lead in the development of point-of-care adult stem cell therapies.
"We believe that point-of-care systems provide an immediate and efficient method for delivering adult stem cell therapy to the patient. Our research has confirmed that the Res-Q system has the features and benefits to deliver consistently high yields of mononuclear cells providing the clinician the best opportunity for successful patient outcomes. Over the next several years we will be working closely with ThermoGenesis and our clinical partners to research and develop continued advancements in the emerging field of regenerative medicine," said Dr. Jim Poser, Executive Vice President of Regenerative Medicine of Celling Technologies.
Celling Technologies is currently launching global distribution of the MXP and RES-Q devices and establishing Institutes of Regenerative Medicine to further research and develop therapies for adult stem cells. The company expects to define the standard of care through clinical performance and potentially lower healthcare costs by offering different means of preventative medicine. As the field matures, Celling and ThermoGenesis will have the expertise and data to drive consistent, reliable outcomes in several areas of medicine, including orthopedics, cardiovascular, trauma and plastics.
About Celling Technologies
Celling Technologies, a SpineSmith Partners company, works closely with surgeons, scientists and engineers to research and develop innovative technologies in the emerging field of regenerative medicine. Celling's product offering focuses on autologous adult stem cell therapy and the
devices and services that complement these procedures.
Round Rock Orthopedics (Round Rock, TX)
Round Rock Orthopedics & Rehab is a comprehensive orthopedic practice specializing in spine surgery, total joint replacement and sports medicine. Their focus is to serve patients in Williamson and surrounding counties, Central Texas, the Texas Hill Country regions and the greater Austin area. Round Rock Orthopedics & Rehab strives to provide state-of-the-art medical care and surgical techniques to change lives and help people live longer.
ThermoGenesis Corporation (Rancho Cordova, CA)
ThermoGenesis Corp. is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. For over 20 years, ThermoGenesis has been dedicated to providing clinicians, researchers, hospitals, and blood banks with systems designed to handle stem cells with the highest levels of precision, safety, and confidence.
SOURCE Celling Technologies
http://www.cellingtechnologies.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
